Myeloproliferative neoplasms (MPNs) are a class of illnesses defined by the development of predominantly mature cells in the circulation. Inherited genetic variations may predispose to acquired proliferation, resulting in uncontrolled myeloid lineage gene mutation. All MPNs have the potential to develop into additional myeloid malignancies, the most frequent of which is AML. The project will investigate the differences between possible novel genetic mutation sites and known mutation locations in MPN patients and their potential relationship with the risk of progression to AML and long-term prognosis. The project duration is about 3 years. The results of this project will demonstrate the differences between possible novel genetic mutation sites and known mutation locations in MPN patients and their potential relationship with the risk of progression to AML and long-term prognosis. Therefore, these findings can provide clinicians and therapists with more information to prevent the development of these diseases and reduce the risk of death from these diseases.
